Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
Carcinoma, Non-Small-Cell Lung | 28 | 2018 | 896 | 4.74 | Why? |
Lung Neoplasms | 37 | 2020 | 3228 | 3.24 | Why? |
Antineoplastic Agents | 29 | 2021 | 3550 | 3.12 | Why? |
Clinical Trials, Phase I as Topic | 11 | 2021 | 242 | 2.54 | Why? |
B7-H1 Antigen | 14 | 2018 | 541 | 2.42 | Why? |
Biomarkers, Tumor | 18 | 2018 | 1314 | 2.09 | Why? |
Antineoplastic Combined Chemotherapy Protocols | 16 | 2018 | 1573 | 1.98 | Why? |
Neoplasms | 49 | 2021 | 17251 | 1.88 | Why? |
Programmed Cell Death 1 Receptor | 14 | 2018 | 724 | 1.81 | Why? |
Protein Kinase Inhibitors | 10 | 2018 | 1585 | 1.75 | Why? |
ErbB Receptors | 6 | 2018 | 320 | 1.54 | Why? |
Piperazines | 3 | 2018 | 445 | 1.25 | Why? |
Endometrial Neoplasms | 2 | 2017 | 120 | 1.23 | Why? |
Immunotherapy | 15 | 2018 | 2421 | 1.17 | Why? |
Erlotinib Hydrochloride | 4 | 2018 | 48 | 1.14 | Why? |
Antineoplastic Agents, Immunological | 8 | 2019 | 830 | 1.10 | Why? |
Pemetrexed | 3 | 2017 | 32 | 1.05 | Why? |
Disease-Free Survival | 14 | 2018 | 1654 | 0.95 | Why? |
Carcinoma, Squamous Cell | 6 | 2018 | 902 | 0.93 | Why? |
Response Evaluation Criteria in Solid Tumors | 3 | 2017 | 37 | 0.93 | Why? |
Cisplatin | 3 | 2017 | 209 | 0.93 | Why? |
Neoplastic Cells, Circulating | 3 | 2019 | 68 | 0.88 | Why? |
Carboplatin | 2 | 2017 | 76 | 0.86 | Why? |
Antibodies, Monoclonal | 15 | 2019 | 8041 | 0.82 | Why? |
Genetic Markers | 2 | 2017 | 318 | 0.79 | Why? |
Genes, erbB | 1 | 2018 | 2 | 0.78 | Why? |
Pyrimidines | 3 | 2017 | 1557 | 0.77 | Why? |
Mutation | 17 | 2019 | 12376 | 0.76 | Why? |
Immunoconjugates | 1 | 2019 | 90 | 0.75 | Why? |
Indazoles | 2 | 2017 | 77 | 0.73 | Why? |
Medical Oncology | 6 | 2021 | 3826 | 0.71 | Why? |
Telomere | 2 | 2010 | 146 | 0.70 | Why? |
Sulfones | 2 | 2017 | 66 | 0.70 | Why? |
Receptor, ErbB-2 | 4 | 2018 | 267 | 0.70 | Why? |
Cryptogenic Organizing Pneumonia | 1 | 2017 | 35 | 0.68 | Why? |
Thiazolidinediones | 1 | 2017 | 70 | 0.68 | Why? |
Sulfoxides | 1 | 2017 | 43 | 0.68 | Why? |
Genetic Testing | 3 | 2018 | 395 | 0.67 | Why? |
DNA Repair | 4 | 2018 | 114 | 0.67 | Why? |
Paclitaxel | 1 | 2017 | 124 | 0.66 | Why? |
Bortezomib | 1 | 2017 | 125 | 0.66 | Why? |
Maximum Tolerated Dose | 8 | 2019 | 65 | 0.63 | Why? |
Bevacizumab | 1 | 2017 | 149 | 0.63 | Why? |
Industry | 1 | 2019 | 347 | 0.59 | Why? |
Patient Selection | 6 | 2021 | 4560 | 0.59 | Why? |
Drug Resistance, Neoplasm | 6 | 2019 | 447 | 0.59 | Why? |
Academies and Institutes | 1 | 2019 | 539 | 0.58 | Why? |
Therapies, Investigational | 1 | 2017 | 235 | 0.56 | Why? |
Patient Reported Outcome Measures | 2 | 2020 | 912 | 0.56 | Why? |
Sirolimus | 3 | 2017 | 240 | 0.53 | Why? |
Carcinoma | 1 | 2017 | 256 | 0.53 | Why? |
Quinazolines | 4 | 2017 | 126 | 0.51 | Why? |
Dose-Response Relationship, Drug | 12 | 2019 | 3776 | 0.50 | Why? |
Cell Cycle Proteins | 2 | 2019 | 297 | 0.48 | Why? |
Protein-Tyrosine Kinases | 3 | 2017 | 158 | 0.47 | Why? |
Otorhinolaryngologic Diseases | 1 | 2017 | 491 | 0.42 | Why? |
Nausea | 4 | 2018 | 457 | 0.41 | Why? |
Oral Ulcer | 1 | 2011 | 70 | 0.41 | Why? |
Kaplan-Meier Estimate | 9 | 2018 | 4260 | 0.39 | Why? |
Sulfonamides | 2 | 2018 | 1294 | 0.39 | Why? |
Precancerous Conditions | 1 | 2010 | 108 | 0.39 | Why? |
Treatment Outcome | 29 | 2020 | 51732 | 0.39 | Why? |
Whole Exome Sequencing | 4 | 2019 | 437 | 0.38 | Why? |
Genomics | 4 | 2018 | 3118 | 0.38 | Why? |
Proliferating Cell Nuclear Antigen | 2 | 2019 | 18 | 0.38 | Why? |
Neoplasm Metastasis | 5 | 2018 | 682 | 0.38 | Why? |
Indoles | 1 | 2017 | 1243 | 0.37 | Why? |
Molecular Targeted Therapy | 8 | 2018 | 1579 | 0.37 | Why? |
Acrylamides | 2 | 2018 | 40 | 0.36 | Why? |
Neoplasms, Radiation-Induced | 1 | 2009 | 60 | 0.36 | Why? |
Carcinoma, Papillary | 1 | 2009 | 76 | 0.36 | Why? |
DNA Damage | 1 | 2010 | 285 | 0.36 | Why? |
Thioxanthenes | 1 | 2007 | 1 | 0.35 | Why? |
Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 130 | 0.35 | Why? |
Breast | 1 | 2010 | 290 | 0.35 | Why? |
Aniline Compounds | 2 | 2018 | 120 | 0.34 | Why? |
Cyclin-Dependent Kinases | 2 | 2017 | 124 | 0.33 | Why? |
Neoplasm Staging | 9 | 2018 | 1999 | 0.32 | Why? |
Aged | 53 | 2021 | 215776 | 0.32 | Why? |
Deoxycytidine | 2 | 2017 | 116 | 0.32 | Why? |
Middle Aged | 59 | 2021 | 270681 | 0.31 | Why? |
Benzamides | 3 | 2018 | 421 | 0.31 | Why? |
Drug Administration Schedule | 3 | 2017 | 2324 | 0.31 | Why? |
Antibodies, Monoclonal, Humanized | 8 | 2021 | 9335 | 0.30 | Why? |
Humans | 107 | 2021 | 930598 | 0.29 | Why? |
Phosphatidylinositol 3-Kinases | 3 | 2017 | 347 | 0.29 | Why? |
Disease Progression | 7 | 2018 | 13580 | 0.29 | Why? |
Signal Transduction | 5 | 2018 | 7207 | 0.28 | Why? |
Female | 66 | 2021 | 380317 | 0.28 | Why? |
High-Throughput Nucleotide Sequencing | 6 | 2018 | 3633 | 0.28 | Why? |
Male | 66 | 2021 | 367725 | 0.28 | Why? |
Thyroid Neoplasms | 1 | 2009 | 422 | 0.26 | Why? |
Pyrazoles | 4 | 2017 | 1791 | 0.26 | Why? |
Aged, 80 and over | 25 | 2021 | 88759 | 0.25 | Why? |
Retreatment | 3 | 2018 | 186 | 0.25 | Why? |
Proto-Oncogene Proteins p21(ras) | 3 | 2017 | 100 | 0.24 | Why? |
Biological Products | 1 | 2017 | 2331 | 0.24 | Why? |
Adult | 44 | 2021 | 244371 | 0.24 | Why? |
Fatigue | 3 | 2018 | 2479 | 0.24 | Why? |
Hematologic Neoplasms | 3 | 2021 | 2105 | 0.24 | Why? |
Lymphoma | 2 | 2017 | 522 | 0.23 | Why? |
Exome | 3 | 2018 | 207 | 0.23 | Why? |
Otorhinolaryngologic Neoplasms | 1 | 2001 | 15 | 0.23 | Why? |
DNA Mutational Analysis | 3 | 2019 | 581 | 0.23 | Why? |
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2017 | 29 | 0.22 | Why? |
Endonucleases | 2 | 2018 | 68 | 0.22 | Why? |
Brain Neoplasms | 2 | 2018 | 669 | 0.22 | Why? |
Drug-Related Side Effects and Adverse Reactions | 3 | 2020 | 1261 | 0.21 | Why? |
Survival Rate | 5 | 2017 | 9206 | 0.21 | Why? |
Breast Neoplasms | 4 | 2018 | 3633 | 0.21 | Why? |
Cell Count | 2 | 2018 | 228 | 0.21 | Why? |
Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 4 | 0.21 | Why? |
France | 10 | 2021 | 12074 | 0.20 | Why? |
Antimetabolites, Antineoplastic | 2 | 2017 | 99 | 0.20 | Why? |
TOR Serine-Threonine Kinases | 2 | 2013 | 385 | 0.20 | Why? |
Linitis Plastica | 1 | 2018 | 1 | 0.19 | Why? |
DNA-Binding Proteins | 3 | 2018 | 469 | 0.19 | Why? |
Acetanilides | 1 | 2018 | 9 | 0.19 | Why? |
Survival Analysis | 9 | 2018 | 7592 | 0.19 | Why? |
Receptor, ErbB-3 | 1 | 2018 | 7 | 0.19 | Why? |
Receptor Protein-Tyrosine Kinases | 2 | 2017 | 243 | 0.18 | Why? |
Clinical Studies as Topic | 1 | 2019 | 118 | 0.18 | Why? |
Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 40 | 0.18 | Why? |
CD27 Ligand | 1 | 2017 | 17 | 0.18 | Why? |
Neoplasms, Experimental | 1 | 2018 | 67 | 0.18 | Why? |
DNA, Neoplasm | 1 | 2017 | 56 | 0.18 | Why? |
Gene Amplification | 2 | 2017 | 85 | 0.18 | Why? |
Predictive Value of Tests | 9 | 2018 | 9537 | 0.18 | Why? |
Germ-Line Mutation | 1 | 2018 | 86 | 0.18 | Why? |
Gastrointestinal Stromal Tumors | 1 | 2018 | 84 | 0.18 | Why? |
Proto-Oncogene Proteins c-met | 1 | 2017 | 40 | 0.18 | Why? |
Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 109 | 0.17 | Why? |
Adenocarcinoma | 2 | 2017 | 651 | 0.17 | Why? |
Antibodies, Anti-Idiotypic | 1 | 2017 | 93 | 0.17 | Why? |
Cytotoxicity, Immunologic | 1 | 2019 | 287 | 0.17 | Why? |
NAD | 1 | 2018 | 73 | 0.17 | Why? |
Evidence-Based Medicine | 2 | 2021 | 3228 | 0.17 | Why? |
Stomach | 1 | 2018 | 141 | 0.17 | Why? |
Microsatellite Instability | 1 | 2017 | 57 | 0.17 | Why? |
Benzodiazepines | 1 | 2019 | 163 | 0.17 | Why? |
Molecular Imaging | 1 | 2018 | 110 | 0.17 | Why? |
Lymphopenia | 2 | 2021 | 2669 | 0.17 | Why? |
Health Status Indicators | 2 | 2018 | 341 | 0.17 | Why? |
Soft Tissue Neoplasms | 1 | 2018 | 131 | 0.16 | Why? |
Diarrhea | 4 | 2018 | 2743 | 0.16 | Why? |
Proteasome Inhibitors | 1 | 2017 | 127 | 0.16 | Why? |
Image-Guided Biopsy | 1 | 2018 | 185 | 0.16 | Why? |
Myocardial Contraction | 1 | 2018 | 123 | 0.16 | Why? |
Meningeal Neoplasms | 1 | 2017 | 48 | 0.16 | Why? |
Biliary Tract Neoplasms | 1 | 2017 | 93 | 0.16 | Why? |
HLA-A2 Antigen | 1 | 2017 | 134 | 0.16 | Why? |
Oropharyngeal Neoplasms | 1 | 2018 | 138 | 0.16 | Why? |
Lymphoma, B-Cell | 1 | 2018 | 166 | 0.16 | Why? |
Metabolome | 1 | 2021 | 624 | 0.16 | Why? |
Anorexia | 1 | 2017 | 194 | 0.16 | Why? |
Prognosis | 16 | 2021 | 32490 | 0.16 | Why? |
Drug Dosage Calculations | 1 | 2017 | 243 | 0.16 | Why? |
Young Adult | 18 | 2021 | 93724 | 0.15 | Why? |
Glioblastoma | 1 | 2018 | 187 | 0.15 | Why? |
Antibody Specificity | 2 | 2018 | 1328 | 0.15 | Why? |
Monitoring, Physiologic | 1 | 2007 | 1956 | 0.15 | Why? |
Precision Medicine | 4 | 2018 | 1477 | 0.15 | Why? |
Small Cell Lung Carcinoma | 1 | 2017 | 133 | 0.15 | Why? |
Vomiting | 2 | 2018 | 722 | 0.15 | Why? |
Heterocyclic Compounds, 3-Ring | 1 | 2018 | 275 | 0.15 | Why? |
Pruritus | 1 | 2017 | 215 | 0.14 | Why? |
Sarcoma | 1 | 2018 | 290 | 0.14 | Why? |
Physicians, Family | 1 | 2018 | 208 | 0.14 | Why? |
Hodgkin Disease | 1 | 2017 | 204 | 0.14 | Why? |
Janus Kinase 1 | 1 | 2017 | 254 | 0.14 | Why? |
Tumor Suppressor Protein p53 | 1 | 2017 | 310 | 0.14 | Why? |
Proto-Oncogene Proteins | 1 | 2017 | 340 | 0.14 | Why? |
Cell-Free Nucleic Acids | 1 | 2017 | 271 | 0.14 | Why? |
Placebos | 1 | 2017 | 629 | 0.14 | Why? |
Comparative Genomic Hybridization | 3 | 2018 | 33 | 0.14 | Why? |
Pyridines | 2 | 2017 | 680 | 0.13 | Why? |
Stomatitis | 1 | 2013 | 57 | 0.13 | Why? |
In Situ Hybridization, Fluorescence | 2 | 2017 | 207 | 0.13 | Why? |
Blood Proteins | 1 | 2017 | 551 | 0.13 | Why? |
Career Choice | 1 | 2019 | 498 | 0.13 | Why? |
Transcription Factors | 1 | 2019 | 784 | 0.13 | Why? |
Central Nervous System | 1 | 2018 | 701 | 0.12 | Why? |
Clinical Trials, Phase III as Topic | 1 | 2017 | 782 | 0.12 | Why? |
Fecal Microbiota Transplantation | 1 | 2017 | 372 | 0.12 | Why? |
Gene Rearrangement | 3 | 2017 | 84 | 0.12 | Why? |
Immune System Diseases | 1 | 2017 | 410 | 0.12 | Why? |
Electrocardiography | 1 | 2007 | 3957 | 0.12 | Why? |
Molecular Diagnostic Techniques | 3 | 2017 | 4239 | 0.12 | Why? |
Stomach Neoplasms | 1 | 2018 | 477 | 0.12 | Why? |
Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
Clinical Trials as Topic | 3 | 2021 | 7330 | 0.12 | Why? |
Immunoenzyme Techniques | 2 | 2016 | 448 | 0.11 | Why? |
Ovarian Neoplasms | 1 | 2017 | 465 | 0.11 | Why? |
Cancer Survivors | 1 | 2018 | 588 | 0.11 | Why? |
Drug Monitoring | 1 | 2019 | 1408 | 0.11 | Why? |
Chemotherapy, Adjuvant | 3 | 2018 | 606 | 0.11 | Why? |
Gene Expression Profiling | 3 | 2018 | 3788 | 0.11 | Why? |
Drug Industry | 1 | 2019 | 689 | 0.11 | Why? |
Practice Guidelines as Topic | 3 | 2020 | 15421 | 0.11 | Why? |
Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 869 | 0.10 | Why? |
Prospective Studies | 9 | 2018 | 43301 | 0.10 | Why? |
Neoplasm Recurrence, Local | 1 | 2017 | 1063 | 0.10 | Why? |
Head and Neck Neoplasms | 2 | 2019 | 1568 | 0.10 | Why? |
Drug Interactions | 1 | 2017 | 1653 | 0.10 | Why? |
Adenocarcinoma, Follicular | 1 | 2009 | 21 | 0.10 | Why? |
Tissue Array Analysis | 1 | 2009 | 75 | 0.10 | Why? |
Quinolines | 1 | 2013 | 403 | 0.10 | Why? |
Papillomavirus Infections | 1 | 2018 | 861 | 0.10 | Why? |
Heparin, Low-Molecular-Weight | 1 | 2018 | 1731 | 0.09 | Why? |
Everolimus | 1 | 2011 | 215 | 0.09 | Why? |
Killer Cells, Natural | 1 | 2019 | 2093 | 0.09 | Why? |
Cetuximab | 2 | 2018 | 35 | 0.09 | Why? |
Early Detection of Cancer | 2 | 2018 | 1956 | 0.09 | Why? |
Transcriptome | 2 | 2018 | 3466 | 0.09 | Why? |
Neoplasm Invasiveness | 1 | 2010 | 582 | 0.09 | Why? |
Antiviral Agents | 1 | 2021 | 41703 | 0.09 | Why? |
DNA Copy Number Variations | 2 | 2018 | 84 | 0.09 | Why? |
Histones | 1 | 2010 | 371 | 0.08 | Why? |
Exons | 2 | 2018 | 158 | 0.08 | Why? |
Enzyme Inhibitors | 1 | 2018 | 1881 | 0.08 | Why? |
Immunomodulation | 1 | 2016 | 1472 | 0.08 | Why? |
Time Factors | 9 | 2021 | 31397 | 0.08 | Why? |
Genetic Variation | 2 | 2018 | 3919 | 0.08 | Why? |
Gene Expression | 1 | 2017 | 3332 | 0.08 | Why? |
Anemia | 1 | 2013 | 789 | 0.08 | Why? |
Area Under Curve | 1 | 2013 | 2564 | 0.08 | Why? |
Mouthwashes | 1 | 2011 | 432 | 0.08 | Why? |
Double-Blind Method | 1 | 2017 | 5988 | 0.08 | Why? |
Pneumonia, Viral | 5 | 2020 | 243684 | 0.08 | Why? |
Tumor Microenvironment | 2 | 2018 | 264 | 0.08 | Why? |
Coronavirus Infections | 5 | 2020 | 253789 | 0.08 | Why? |
Health Care Rationing | 1 | 2020 | 2558 | 0.08 | Why? |
Proportional Hazards Models | 4 | 2020 | 6543 | 0.07 | Why? |
Pneumonectomy | 2 | 2018 | 278 | 0.07 | Why? |
Carcinoma, Small Cell | 1 | 2004 | 16 | 0.07 | Why? |
Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
Lymphocytes | 1 | 2017 | 3056 | 0.07 | Why? |
Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
Telomerase | 1 | 2004 | 45 | 0.07 | Why? |
Betacoronavirus | 5 | 2020 | 204454 | 0.07 | Why? |
Gastrointestinal Microbiome | 1 | 2017 | 1961 | 0.07 | Why? |
Sequence Analysis, DNA | 3 | 2018 | 2830 | 0.07 | Why? |
Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
Gene Expression Regulation, Neoplastic | 2 | 2016 | 1014 | 0.07 | Why? |
Echocardiography | 1 | 2018 | 3661 | 0.07 | Why? |
Serum Albumin | 2 | 2017 | 571 | 0.06 | Why? |
Recurrence | 3 | 2017 | 3675 | 0.06 | Why? |
Retrospective Studies | 13 | 2018 | 105322 | 0.06 | Why? |
Neoplasm Proteins | 2 | 2018 | 501 | 0.06 | Why? |
Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
Phenotype | 3 | 2018 | 4037 | 0.06 | Why? |
Computational Biology | 1 | 2018 | 4514 | 0.06 | Why? |
Immunohistochemistry | 3 | 2018 | 2275 | 0.06 | Why? |
Drug Repositioning | 1 | 2021 | 5683 | 0.06 | Why? |
Micrococcaceae | 1 | 2021 | 72 | 0.06 | Why? |
Immunoassay | 1 | 2018 | 4485 | 0.06 | Why? |
Referral and Consultation | 1 | 2018 | 4816 | 0.06 | Why? |
Anti-Inflammatory Agents | 1 | 2021 | 6153 | 0.06 | Why? |
Internet | 1 | 2020 | 6204 | 0.06 | Why? |
Anticarcinogenic Agents | 1 | 2001 | 25 | 0.06 | Why? |
Multivariate Analysis | 3 | 2017 | 5440 | 0.06 | Why? |
Genetic Predisposition to Disease | 4 | 2018 | 4027 | 0.06 | Why? |
Biomarkers | 3 | 2021 | 23361 | 0.06 | Why? |
Risk Factors | 8 | 2020 | 71621 | 0.06 | Why? |
Hospitals | 1 | 2021 | 11793 | 0.06 | Why? |
Chromosome Aberrations | 1 | 2001 | 54 | 0.06 | Why? |
CD8-Positive T-Lymphocytes | 1 | 2018 | 5837 | 0.05 | Why? |
Reproducibility of Results | 4 | 2018 | 11304 | 0.05 | Why? |
Immunologic Factors | 1 | 2017 | 4206 | 0.05 | Why? |
Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
Neutrophils | 1 | 2017 | 5476 | 0.05 | Why? |
Animals | 6 | 2019 | 78931 | 0.05 | Why? |
Fever | 1 | 2017 | 7795 | 0.05 | Why? |
Mice, Inbred NOD | 1 | 2019 | 134 | 0.05 | Why? |
Acneiform Eruptions | 1 | 2018 | 4 | 0.05 | Why? |
Tumor Cells, Cultured | 1 | 2019 | 254 | 0.05 | Why? |
Oximes | 1 | 2018 | 51 | 0.05 | Why? |
Mice, SCID | 1 | 2019 | 225 | 0.05 | Why? |
Tubulin | 1 | 2018 | 67 | 0.05 | Why? |
Quality of Life | 2 | 2017 | 9820 | 0.05 | Why? |
L-Lactate Dehydrogenase | 2 | 2017 | 1995 | 0.05 | Why? |
Ploidies | 1 | 2018 | 5 | 0.05 | Why? |
Combined Modality Therapy | 2 | 2018 | 3395 | 0.05 | Why? |
RNA, Neoplasm | 1 | 2018 | 34 | 0.05 | Why? |
Receptors, Notch | 1 | 2018 | 59 | 0.05 | Why? |
Xenograft Model Antitumor Assays | 1 | 2019 | 274 | 0.05 | Why? |
Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 30 | 0.05 | Why? |
Verrucomicrobia | 1 | 2017 | 6 | 0.05 | Why? |
Ipilimumab | 1 | 2018 | 102 | 0.05 | Why? |
Receptors, CCR | 1 | 2017 | 26 | 0.05 | Why? |
Vaccination | 2 | 2021 | 19050 | 0.05 | Why? |
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 15 | 0.04 | Why? |
Chromosomes, Human, Pair 8 | 1 | 2017 | 25 | 0.04 | Why? |
Severity of Illness Index | 3 | 2017 | 48226 | 0.04 | Why? |
Oncogene Fusion | 1 | 2017 | 1 | 0.04 | Why? |
Platinum Compounds | 1 | 2017 | 20 | 0.04 | Why? |
Entropy | 1 | 2017 | 52 | 0.04 | Why? |
Stress, Mechanical | 1 | 2018 | 143 | 0.04 | Why? |
Asthenia | 1 | 2018 | 107 | 0.04 | Why? |
Alternative Splicing | 1 | 2018 | 82 | 0.04 | Why? |
Cell Cycle Checkpoints | 1 | 2018 | 126 | 0.04 | Why? |
Sensitivity and Specificity | 2 | 2017 | 22971 | 0.04 | Why? |
Genetic Heterogeneity | 1 | 2017 | 77 | 0.04 | Why? |
Receptors, CXCR3 | 1 | 2017 | 159 | 0.04 | Why? |
Lactams | 1 | 2017 | 50 | 0.04 | Why? |
Enterobacteriaceae | 1 | 2021 | 395 | 0.04 | Why? |
Liquid Biopsy | 1 | 2017 | 114 | 0.04 | Why? |
Mice, Nude | 1 | 2018 | 340 | 0.04 | Why? |
Tissue Distribution | 1 | 2019 | 483 | 0.04 | Why? |
Odds Ratio | 2 | 2020 | 5861 | 0.04 | Why? |
Biomechanical Phenomena | 1 | 2018 | 291 | 0.04 | Why? |
CTLA-4 Antigen | 1 | 2018 | 282 | 0.04 | Why? |
Cancer Vaccines | 1 | 2018 | 136 | 0.04 | Why? |
Heterozygote | 1 | 2018 | 249 | 0.04 | Why? |
Homozygote | 1 | 2018 | 230 | 0.04 | Why? |
DNA, Bacterial | 1 | 2021 | 835 | 0.04 | Why? |
Interleukin-12 | 1 | 2017 | 156 | 0.04 | Why? |
Protein Isoforms | 1 | 2018 | 347 | 0.04 | Why? |
Lactams, Macrocyclic | 1 | 2017 | 130 | 0.04 | Why? |
Biphenyl Compounds | 1 | 2018 | 249 | 0.04 | Why? |
Biomedical Research | 1 | 2017 | 5270 | 0.04 | Why? |
Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
Anilides | 1 | 2017 | 105 | 0.04 | Why? |
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 43 | 0.04 | Why? |
Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
CD4 Antigens | 1 | 2017 | 306 | 0.04 | Why? |
Aminopyridines | 1 | 2017 | 121 | 0.04 | Why? |
Age of Onset | 1 | 2018 | 557 | 0.04 | Why? |
Morpholines | 1 | 2018 | 351 | 0.04 | Why? |
Neoplasm Grading | 1 | 2017 | 400 | 0.04 | Why? |
Software | 2 | 2018 | 2501 | 0.04 | Why? |
Febrile Neutropenia | 1 | 2018 | 179 | 0.04 | Why? |
Clone Cells | 1 | 2016 | 312 | 0.04 | Why? |
Metagenome | 1 | 2017 | 268 | 0.04 | Why? |
Observer Variation | 1 | 2018 | 622 | 0.04 | Why? |
Lymphocyte Count | 2 | 2017 | 4758 | 0.04 | Why? |
Case-Control Studies | 2 | 2018 | 17671 | 0.04 | Why? |
Serum Albumin, Human | 1 | 2017 | 265 | 0.04 | Why? |
Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
Mutation Rate | 1 | 2017 | 382 | 0.04 | Why? |
Metabolomics | 1 | 2021 | 921 | 0.04 | Why? |
Proto-Oncogene Proteins c-akt | 1 | 2017 | 372 | 0.04 | Why? |
Cardiotoxicity | 1 | 2018 | 365 | 0.03 | Why? |
Antigens, Neoplasm | 1 | 2016 | 230 | 0.03 | Why? |
Polypharmacy | 1 | 2017 | 347 | 0.03 | Why? |
Clinical Trials, Phase II as Topic | 1 | 2018 | 801 | 0.03 | Why? |
Tomography, X-Ray Computed | 2 | 2018 | 25144 | 0.03 | Why? |
Blood-Brain Barrier | 1 | 2018 | 531 | 0.03 | Why? |
Proto-Oncogene Proteins B-raf | 1 | 2016 | 179 | 0.03 | Why? |
Infection Control | 2 | 2020 | 23131 | 0.03 | Why? |
Mice | 3 | 2019 | 21357 | 0.03 | Why? |
Genome, Human | 1 | 2018 | 400 | 0.03 | Why? |
Immunotherapy, Adoptive | 1 | 2018 | 524 | 0.03 | Why? |
Viremia | 1 | 2021 | 1020 | 0.03 | Why? |
Colonic Neoplasms | 1 | 2018 | 295 | 0.03 | Why? |
Drug Eruptions | 1 | 2018 | 319 | 0.03 | Why? |
Probability | 1 | 2018 | 923 | 0.03 | Why? |
Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
Oncologists | 1 | 2020 | 877 | 0.03 | Why? |
RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.03 | Why? |
Urologic Neoplasms | 1 | 2018 | 348 | 0.03 | Why? |
Gene Frequency | 1 | 2018 | 1210 | 0.03 | Why? |
Patient Outcome Assessment | 1 | 2017 | 707 | 0.03 | Why? |
Multimodal Imaging | 1 | 2017 | 534 | 0.03 | Why? |
Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
Hematologic Tests | 1 | 2017 | 521 | 0.03 | Why? |
Pandemics | 7 | 2021 | 389249 | 0.03 | Why? |
Withholding Treatment | 1 | 2018 | 798 | 0.03 | Why? |
Radiotherapy | 1 | 2017 | 608 | 0.03 | Why? |
Age Factors | 3 | 2018 | 21039 | 0.03 | Why? |
DNA | 1 | 2018 | 778 | 0.03 | Why? |
Protein Multimerization | 1 | 2018 | 1336 | 0.03 | Why? |
Alleles | 1 | 2018 | 1557 | 0.03 | Why? |
A549 Cells | 1 | 2018 | 2066 | 0.03 | Why? |
Databases, Genetic | 1 | 2018 | 1127 | 0.03 | Why? |
Cell Proliferation | 1 | 2019 | 1973 | 0.03 | Why? |
Sequence Alignment | 1 | 2018 | 2109 | 0.03 | Why? |
Image Interpretation, Computer-Assisted | 1 | 2018 | 665 | 0.03 | Why? |
Prostatic Neoplasms | 1 | 2004 | 1637 | 0.03 | Why? |
Infant | 2 | 2017 | 30274 | 0.03 | Why? |
Carcinoma, Renal Cell | 1 | 2018 | 545 | 0.03 | Why? |
Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
Child, Preschool | 2 | 2017 | 36283 | 0.03 | Why? |
Disease Management | 2 | 2018 | 6841 | 0.02 | Why? |
Safety | 1 | 2017 | 1583 | 0.02 | Why? |
Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
Kidney Neoplasms | 1 | 2018 | 832 | 0.02 | Why? |
Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
Sequence Analysis, RNA | 1 | 2018 | 2290 | 0.02 | Why? |
Lung | 1 | 2018 | 31049 | 0.02 | Why? |
Apoptosis | 1 | 2019 | 2335 | 0.02 | Why? |
Geriatric Assessment | 1 | 2017 | 1372 | 0.02 | Why? |
Biopsy | 1 | 2017 | 2811 | 0.02 | Why? |
Mice, Inbred C57BL | 1 | 2019 | 5542 | 0.02 | Why? |
Risk | 1 | 2020 | 5288 | 0.02 | Why? |
Interferon Type I | 1 | 2021 | 2789 | 0.02 | Why? |
Immunization Programs | 1 | 2020 | 2006 | 0.02 | Why? |
Equipment Design | 1 | 2018 | 3095 | 0.02 | Why? |
Risk Assessment | 1 | 2011 | 25439 | 0.02 | Why? |
Melanoma | 1 | 2018 | 1229 | 0.02 | Why? |
Amino Acid Sequence | 1 | 2018 | 6049 | 0.02 | Why? |
Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
Survivors | 1 | 2017 | 2619 | 0.02 | Why? |
Neoplasms, Hormone-Dependent | 1 | 2004 | 25 | 0.02 | Why? |
Child | 2 | 2017 | 70012 | 0.02 | Why? |
Polymorphism, Single Nucleotide | 1 | 2018 | 3607 | 0.02 | Why? |
Feces | 1 | 2017 | 4235 | 0.02 | Why? |
Health Status | 1 | 2017 | 3259 | 0.02 | Why? |
Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
Forecasting | 1 | 2017 | 4492 | 0.02 | Why? |
Computer Simulation | 1 | 2018 | 4982 | 0.02 | Why? |
Ambulatory Care | 1 | 2020 | 4947 | 0.02 | Why? |
Cell Line | 1 | 2018 | 12040 | 0.01 | Why? |
Nasopharynx | 1 | 2021 | 10224 | 0.01 | Why? |
Blotting, Western | 1 | 2004 | 863 | 0.01 | Why? |
Aging | 1 | 2017 | 3581 | 0.01 | Why? |
Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
T-Lymphocytes | 1 | 2017 | 6670 | 0.01 | Why? |
Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
Registries | 1 | 2018 | 12327 | 0.01 | Why? |
Catalytic Domain | 1 | 2004 | 1757 | 0.01 | Why? |
Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
Infant, Newborn | 1 | 2017 | 23105 | 0.01 | Why? |
Cytokines | 1 | 2018 | 15010 | 0.01 | Why? |
Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
Prevalence | 1 | 2017 | 25773 | 0.01 | Why? |
Public Health | 1 | 2020 | 16359 | 0.01 | Why? |
Delivery of Health Care | 1 | 2020 | 15909 | 0.01 | Why? |
Environmental Exposure | 1 | 2004 | 1558 | 0.01 | Why? |
Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
Telemedicine | 1 | 2020 | 25032 | 0.01 | Why? |